All In Biotech

Drug Trial Radar · NCT04525391

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Phase II, Single-arm Study of AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer Subjects [SUKSES-N5]

Last checked: Nov 19, 2026Latest source record: Feb 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Sep 18, 2020

Primary completion

Jan 14, 2022

Study completion Jan 14, 2022

Sponsor

Lead sponsor
Se-Hoon LeeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Samsung Medical Centre, Seoul, Korea. Additional 0\~5 Korea Lung Cancer Consortium (KLCC) centres in Korea Up to 40 subjects will be enrolled in two-stages (first stage: 19 evaluable subjects and second stage: 17 evaluable subjects and additional 4 subjects considering the drop out rate) If the study is conducted as de-escalated dosage (Durvalumab 1120mg) after the safety run-in, number of the patients will be counted from the second safety-run in phase.

Conditions

  • SCLC, Recurrent

Interventions

  • Durvalumab+AZD2811 to SCLC patientsDrug

    AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease control rate is defined as the proportion of patients with best response of CR, PR, or who have SD for at least 12 weeksTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, Gangnam-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.